Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Aptuit | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Aptuit

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Timothy C. Tyson has been appointed executive chairman and acting chief executive officer of Aptuit, Inc. Michael A. Griffith, the company’s founder and chief executive officer since 2005, has resigned to pursue other opportunities.
    
“The board wishes to thank Mike for his outstanding success in creating a world-class organization that is a trusted partner to hundreds of innovative clients throughout the world,” said Tony Ecock, outgoing chairman of Aptuit’s board of managers. “With 2,700 employees working with more than 800 clients throughout the world, Aptuit has established a solid foundation for continued growth and success.”
   
Tim Tyson is the former chief operating officer, president and chief executive officer of Valeant Pharmaceuticals International, where he served from 2002-2008. Prior to Valeant, Mr. Tyson spent 14 years at GlaxoSmithKline, where he was president of global manufacturing and supply and ran Glaxo Dermatology and Cerenex Pharmaceuticals. He managed all sales and marketing for GlaxoWellcome’s U.S. operations. Mr. Tyson has also held executive positions at Bristol-Myers in commercial and technical operations and R&D. Previously he was a manufacturing manager for Procter & Gamble.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters